Fresenius stock pre-market at EUR 44.10: minus 0.02 percent
Published on 10/06/2026 at 07:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius stock is at EUR 44.10 pre-market at Lang & Schwarz as of 7:48 a.m. CEST on October 6, 2026. The price is down EUR 0.01, or minus 0.02 percent, versus the Lang & Schwarz prior close of EUR 44.11 on October 5, 2026.
Fresenius pre-market price
The bid is EUR 44.04 and the ask is EUR 44.17 at Lang & Schwarz. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Fresenius stock.
Previous close
Fresenius shares closed at EUR 44.11 at Lang & Schwarz on October 5, 2026. Fresenius SE & Co. KGaA is traded on Xetra under the ticker FRE, according to the company's securities information.
mAbxience acquisition completed
In a Fresenius release dated October 1, 2026, the company said it had acquired the remaining 45 percent of mAbxience Holding S.L. from Insud Pharma S.L. and Invim Corporativo, S.L. The transaction was signed and completed on September 30, 2026, with total consideration of up to EUR 750 million, including a contingent payment of EUR 50 million upon site approvals.
Fresenius said the acquisition gives it full ownership of the biosimilars platform within Fresenius Kabi's Biopharma business. The company said no new financing was required and that the transaction would be immediately accretive to Group core earnings per share. It also said full-year 2026 guidance was unchanged. Linklaters separately described the deal as creating a fully integrated biopharma business consolidated within Fresenius Kabi.
